Predictors of uropathogens other than Escherichia coli in patients with community-onset acute pyelonephritis

Summary Aim A constant reduction in the incidence of community‐onset acute pyelonephritis (CO‐APN) caused by Escherichia coli has been shown with a parallel increase incidence caused by other organisms. Therefore, we evaluated the risk factors and outcome of non‐E. coli as uropathogens in patients w...

Full description

Saved in:
Bibliographic Details
Published in:International journal of clinical practice (Esher) 2014-06, Vol.68 (6), p.749-755
Main Authors: Wi, Y. M., Kim, S.-W., Chang, H.-H., Jung, S.-I., Kim, Y.-S., Cheong, H. S., Ki, H. K., Son, J. S., Kwon, K. T., Heo, S. T., Yeom, J.-S., Ko, K. S., Kang, C. I., Chung, D. R., Peck, K. R., Song, J.-H.
Format: Article
Language:English
Subjects:
Antibiotics
Clinical outcomes
Community-Acquired Infections
Escherichia coli
Humans
Kidney diseases
Male
Microbial Sensitivity Tests - utilization
Pathogens
Pyelonephritis - etiology
Republic of Korea
Risk Factors
Urinary tract diseases
Urinary Tract Infections - etiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Aim A constant reduction in the incidence of community‐onset acute pyelonephritis (CO‐APN) caused by Escherichia coli has been shown with a parallel increase incidence caused by other organisms. Therefore, we evaluated the risk factors and outcome of non‐E. coli as uropathogens in patients with community‐onset APN. Methods As a part of a nationwide multicentre surveillance study conducted in Korea, a total of 416 patients with CO‐APN were collected with their epidemiological, antibiotic treatment and outcome data. Results The risk factors and outcomes of non‐E. coli as uropathogens were evaluated in a total of 416 patients with culture‐confirmed CO‐APN. Non‐E. coli caused 127 cases (30.5%) of CO‐APN. CO‐APN caused by non‐E. coli resulted in higher inappropriate empirical therapy (38.6% vs. 20.1%, p 
ISSN:1368-5031
1742-1241
DOI:10.1111/ijcp.12368